tunlametinib
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
1
Earliest trial started Sep 22, 2023 (NCT06008106)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NOCCO)c1cc2scnc2c(F)c1Nc1ccc(I)cc1F- Mol. weight
- 491.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095241 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170293 | Phase 2 | Aug 31, 2027 | Tianjin Medical University |
| NCT07302841 | Phase 4 | Jan 20, 2026 | Tianjin Medical University |
| NCT06970353 | Phase 2 | May 27, 2025 | Fudan University |
| NCT06985316 | N/A | May 19, 2025 | Huazhong University of Science and Technology |
| NCT06008119 | Phase 3 | Nov 24, 2023 | Kechow Pharma |
| NCT06008106 | Phase 3 | Sep 22, 2023 | Kechow Pharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kechow Pharma | For profit | 2 | 2 | 1 | 2023 |
| Tianjin Medical University | Academic/Hospital | 2 | 2 | 2 | 2026 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1